Moreover, the ICC requires a 10% blast threshold to define AML with recurrent genetic abnormalities (excluding BCR::ABL and TP53), unlike WHO-2022, where most AML with defining genetic abnormalities can be diagnosed with increased blasts in peripheral blood (PB) or bone marrow (BM) (may be <20%). This evidence concerns the gene BCR and acute myeloid leukemia.